Kornimate/medical-research-clean huggingface dataset:
endovascular therapy for renal artery stenosis in china

Conditions: Renal Artery Obstruction; Hypertension, Renovascular

Summary: a multicenter prospective registry planned to recruit more than 5 000 patients with renal artery stenosis was carried out in china. this primary purpose of this study was to evaluate the safety and efficacy of renal artery revascularization in the real world. the secondary purpose was to investigate the etiologic distribution of renal artery stenosis and optimize the indications for renal artery revascularization.

currently,the endovascular therapy of renal artery stenosis (especially atherosclerotic) remains in dispute. some randomized control trials published in recent years (including astral and coral trials) showed the lack of additional benefit for renal artery revascularization compared with sole medical therapy. however,these randomized control trials presented a number of limitations including low numbers of patients and non-stringent inclusion criteria. given clinical medical practice entering the era of big data, the large-sample real-word studies would be more objective to answer some pending issues of randomized controlled trial.therefore,a multicenter prospective registry planned to recruit more than 5 000 patients with renal artery stenosis was carried out. this primary purpose of this study was to evaluate the safety and efficacy of renal artery revascularization in the real world. the secondary purpose was to investigate the etiologic distribution of renal artery stenosis and optimize the indications for renal artery revascularization.

Eligibility criteria:
inclusion criteria: 1. age ≥ 14 at the time of informed consent 2. diameter reduction of renal artery or main branch of renal artery≥ 60%,and ≥2 of four following conditions met:1)systolic hyperemic pressure gradient \>20 mm hg,2)captopril renoscitigraphy positive in the lesion side ,3)renin-angiotensin-aldosterone system significantly activated and 4)severe reduction (\>25%) of glomendar filtration rate in the lesion side 3. office systolic blood pressure ≥140 mmhg and/or diastolic blood pressure ≥90 mmhg while receiving 3 antihypertensive drugs,or office systolic blood pressure ≥160 mmhg and/or diastolic blood pressure ≥100 mmhg without antihypertensive drugs 4. serum creatinine level\<264umol/l 5. length of ipsilateral kidney ≥7.0 cm and glomendar filtration rate ≥10 ml／min 6. urine protein \<2+ exclusion criteria: 1. unable to provide informed consent 2. unstable condition and unable to tolerate interventional therapy 3. intolerance to antiplatelet drugs or contrast medium 4. vascular anatomy not suitable for endovascular therapy 5. pregnant, nursing, or planning to be pregnant

Keywords: renal artery stenosis balloon angioplasty stents
amprenavir/ritonavir or saquinavir/ritonavir in hiv-infected subjects following failure with kaletra as their second protease inhibitor

Conditions: HIV Infections

Summary: the purpose of this study is to study the safety and efficacy of amprenavir/ritonavir or saquinavir/ritonavir in hiv infected patients that have failed kaletra as their second protease inhibitor based haart.


Eligibility criteria:
inclusion: * subject must remain on current antiretroviral therapy during screening until a new regimen is initiated. * subject demonstrates reduced susceptibility to lopinavir. * subject's two most recent viral loads obtained after at least 16 weeks of lopinavir/ritonavir therapy, and while still on kaletra therapy must be at least 1,000 copies/ml. * the kaletra regimen must be the subject's second pi containing regimen and must not contain any other pis. * subject is at least 18 years of age. * subject has not been treated for an active opportunistic infection within 30 days of screening. exclusion: * subject has a history of active substance abuse or psychiatric illness that could preclude compliance to the protocol. * female subject pregnant or lactating. * use of an investigational drug within 30 days prior to the initiation of drug dosing. * subject is receiving systemic chemotherapy. * subject has a history of acute or chronic pancreatitis.

Keywords: treatment experienced hiv
role of fenofibrate in indirect neonatal hyperbilirubinemia: a randomized control trial

Conditions: Hyperbilirubinemia, Neonatal

Summary: fenofibrate accelerates bilirubin conjugation and excretion, decreasing the side effects of prolonged unconjugated hyperbilirubinemia in neonates. it also reduces the duration of phototherapy and thus the duration of stay in the hospital. this research is carried out to improve standard protocol for the management of neonatal hyperbilirubinemia in the local settings.

complete history and examination will be carried out while patients will be screened for enrollment. after taking informed consent, eligible patients will be selected and divided into two groups a and b by lottery method. demographics like name, age (hours), gender, birth weight, and gestational age will be noted. solutions will be prepared in the required strengths and labeled accordingly. groups a will receive solution a i.e. fenofibrate suspension is prepared by dissolving 200 mg capsule in 10 ml distilled water and given as a single dose of 10mg/kg (0.5 ml/kg) and group b will receive solution b i.e. 0.5ml/ kg normal saline as a placebo. both groups will receive led phototherapy under standard conditions. the serum bilirubin level will be noted at the time of admission and then at 12hr, 24hr, and 48 hours of treatment. all this information will be recorded on proforma.

Eligibility criteria:
inclusion criteria: * gestational age ≥ 35 weeks * birth weight ≥ 2 kg * age: 2-7 days of life * total serum bilirubin level ≥15mg/dl and ≤20 mg/dl exclusion criteria: * neonates with total bilirubin \>20mg/dl * conjugated bilirubin level greater than 15% of total serum bilirubin * maternal hyperbilirubinemia (on medical record) * babies with congenital anomalies (on clinical examination) * those not consenting to participate in the study
azithromycin in bronchiolitis obliterans syndrome

Conditions: Bronchiolitis Obliterans Syndrome; Graft Rejection; Lymphocytic Bronchiolitis; Respiratory Infection

Summary: preventive treatment with azithromycin reduces the prevalence fo bronchiolitis obliterans syndrome after lung transplantation.

* prospective, interventional, randomized, double-blind, placebo-controlled trial. * clinical setting (tertiary university hospital). * investigator-driven, no pharmaceutical sponsor. * lung transplant recipients. * add-on of study-drug (placebo or azithromycin) to 'standard of care' (standardized, routine immunosuppressive and infectious prophylactic protocol). * 1:1 inclusion ratio (placebo:azithromycin). * randomisation at discharge after informed consent.

Eligibility criteria:
inclusion criteria: * stable ltx recipients at discharge after transplantation. * signed informed consent * adult (age at least 18 years old at moment of transplantation) * able to take oral medication exclusion criteria: * prolonged and/or complicated icu-course after transplantation. * early (\<30 days post-transplant) post-operative death * major suture problems (airway stenosis or stent) * retransplantation (lung) * previous transplantation (solid organ) * multi-organ transplantation (lung+ other solid organ)

Keywords: bronchiolitis obliterans syndrome acute allograft rejection lymphocytic bronchiolitis respiratory infection survival mortality pulmonary function fev1 broncho-alveolar lavage neutrophils interleukin culture azithromycin
buprenorphine plus baclofen to increase analgesia in healthy volunteers

Conditions: Acute Pain; Analgesia

Summary: to determine if baclofen will enhance buprenorphine analgesia for acute pain in healthy volunteers.

abuse of opioids is a significant and growing problem in the united states. in the past two decades, opioid prescriptions have quadrupled while the age of heroin initiation has decreased, suggesting that more individuals are using opioids and transitioning to heroin and potent synthetic opioids than in the past. further, fatal opioid overdose is now the leading cause of accidental death and is the 5th highest overall cause of mortality in the us. engaging opioid users in opioid agonist treatments has been shown to lower rates of criminal behavior, lower rates of non-opioid drug use, and increase retention in drug treatment programs, while decreasing mortality and new hiv and hepatitis infections. however, a recent study noted that 68% of patients prescribed buprenorphine had poor medication adherence, which was associated with illicit opioid use. a cochrane review concluded that buprenorphine was less effective at retaining patients in treatment relative to methadone. one reason for lower treatment retention may be the high comorbidity of opioid use disorder and chronic pain and/or opioid-induced hyperalgesia. buprenorphine, as a partial mu agonist, provides lower analgesia but an improved safety profile relative to full agonists like methadone. thus, enhancing the analgesic properties of buprenorphine will provide a safer alternative for opioid use disorder patients with chronic pain/hyperalgesia.

Eligibility criteria:
inclusion criteria: * 18 years or older * general good health * english speaking exclusion criteria: * pregnant or nursing * opioid use disorder or any substance use disorder other than nicotine * prescribed agonist treatment for opioid dependence or prescribed opioids for a medical condition * prescribed naltrexone * known sensitivity to buprenorphine, naloxone, or baclofen * acute or chronic pain condition * trouble breathing or a pulmonary condition * prescribed benzodiazepines or daily use of benzodiazepines * positive drug screen (positive cannabis result allowed) * cognitive impairment or psychiatric disorder requiring treatment * uncontrolled hypertension
an extension study of abt-806 in subjects with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this is an extension study of abt-806 for subjects with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * subject has completed a prior study utilizing abt-806 or 111ln abt-806 (abt 806i) and the investigator believes that continued treatment with abt-806 is in the best interest of the subject. * women of childbearing potential and men must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation and for a period of 3 months. female subjects considered not of childbearing potential must be documented as being surgically sterile or post-menopausal for at least 1 year. * subject is capable of understanding and complying with parameters as outlined in the protocol and the subject or the subject's legal acceptable representative is able to sign informed consent, approved by an institutional review board (irb) prior to the initiation of any or study-specific procedures. exclusion criteria: * subject discontinued abt-806 or111ln abt-806 (abt-806i) administration before completing the prior study (due to disease progression, toxicity, withdrawn consent, other). * subject has any medical condition which in the opinion of the investigator places the subject at an unacceptably high risk for toxicities. * subject is a lactating or pregnant female.
clinical characteristics of lymphatic malformations

Conditions: Lymphatic Malformation; Lymphangioma

Summary: the primary purpose of this study is to retrospectively identify the clinical characteristics of abdominal lymphatic malformations (alms) in our single center in china. the second objective of this study is to retrospectively compare the epidemiological features, clinical presentations, cyst properties, surgical treatments, and risk factors for preoperative complications of alms between paediatric participants and adult participants.

lymphatic malformations (lms) are vascular anomalies that arise from abnormal embryonic development of the lymphatic system and can present as dilated lymphatic channels or cysts lined by lymphatic endothelial cells. abdominal lymphatic malformations (alms) are rare entities that account for fewer than 10% of lms and may occur not only in the tissues or organs in the abdominal cavity, such as the mesentery, spleen and pancreas but also in the retroperitoneal space. alms can manifest as an infection, chronic abdominal discomfort, acute abdomen, or fatal disease.

Eligibility criteria:
inclusion criteria: * the investigators enrolled participants who were pathologically diagnosed with lymphangioma or lymphatic malformations in the abdominal cavity (i.e., abdominal lymphatic malformations) from january 2009 to december 2022 at our institution. exclusion criteria: * the investigators excluded participants without a pathological diagnosis of abdominal lymphatic malformations through resection specimens and those with pathological confirmation of other diseases, as well as patients with complex lymphatic anomalies.

Keywords: lymphatic malformation abdominal site preoperative complications resection mesentery acute abdomen
a study to assess analgesic efficacy of intravenous lignocaine

Conditions: Postoperative Pain; Postoperative Nausea and Vomiting; Postoperative Ileus

Summary: the primary objectives of this study are to analyse the effect of perioperative systemic infusion of lignocaine on postoperative pain, postoperative nausea and vomiting and perioperative levels of inflammatory mediators in patients undergoing elective open abdominal surgeries. the secondary parameters which will be observed during the study are the time to passage of flatus and stools postoperatively.

patients will be randomized into two groups- a and b, to receive an intravenous infusion of lignocaine or saline,respectively, as a bolus of 1.5mg/kg at the time of intubation followed by an infusion at a rate of 1.5mg/kg/hr continued throughout the surgery and till one hour postop. postoperative analgesia will be provided through patient controlled analgesia (pca) pump providing morphine. postoperative pain scores will be noted at immediate postoperative and at 6, 18, 24 hours post surgery. the number of pca demands and cumulative morphine consumption till 24 hours post surgery will be noted. the incidence of postoperative nausea and vomiting is recorded. the time to first passage of flatus and stools postoperatively will be noted. levels of total leukocyte count, c-reactive protein (crp) and interleukin-6(il-6) will be noted in preoperative, immediate post operative and 24 hours post surgery.

Eligibility criteria:
inclusion criteria: * patients above 18 years of age * undergoing elective open abdominal surgeries * belonging to the american society of anaesthesiologists (asa)status i,ii,iii exclusion criteria: * patients sensitive to lignocaine, * patients suffering from cardiovascular diseases or with preoperative changes on electrocardiogram * patients on beta blocker drugs * patients on opioid drugs for prolonged period * patients with functional bowel disorders

Keywords: perioperative lignocaine infusion elective open abdominal surgeries postoperative pain
pilot study of ruxolitinib in relapsed or refractory hodgkin lymphoma and primary mediastinal large b-cell lymphoma

Conditions: Relapsed or Refractory Hodgkin Lymphoma; Primary Mediastinal Large B-cell Lymphoma

Summary: the purpose of this study is that ruxolitinib may be a possible treatment option for relapsed or refractory patients with hodgkin and primary mediastinal large b-cell lymphoma.

patients will take ruxolitinib 20 mg orally twice a day, 40mg in total per day, for 4 weeks.4 weeks is 1 cycle. treatment will be continued until documented disease progression or unacceptable toxicity and the maximum period of treatment is 16 cycles.

Eligibility criteria:
inclusion criteria: * histologically proven hodgkin lymphoma or primary mediastinal large b-cell lymphoma * patient should belong to any one of following clinical situations a.patient who are not able to get autologous stem cell transplantation after relapsing the salvage chemotherapy b. relapsed after autologous stem cell transplantation c. refractory to salvage chemotherapy or autologous stem cell transplantation * adequate organ function as defined by the following criteria: a. serum aspartate transaminase (ast; serum glutamic oxaloacetic transaminase (sgot)) and serum alanine transaminase (alt; serum glutamic pyruvic transaminase (sgpt)) ≤2.5 x local laboratory upper limit of normal (uln), or ast and alt less than or equal to 5 x uln if liver function abnormalities are due to underlying malignancy b. total serum bilirubin ≤1.5 x uln c. absolute neutrophil count (anc) ≥ 1500/µl d. platelets ≥ 100,000/µl e. hemoglobin ≥ 9.0 g/dl (may be transfused or erythropoietin treated) f. serum calcium ≤ 12.0 mg/dl g. serum creatinine ≤ 1.5 x uln * at least one measurable lesion * ecog ps 0-2 * informed consent * age from 19 to 80 exclusion criteria: * previously received allogeneic stem cell transplantation * history of or known carcinomatous meningitis, or evidence of symptomatic leptomeningeal disease or secondary cns involvement on ct or mri scan. * currently uncontrolled active infection * previous history of recurrent herpes zoster or recurrent tuberculosis * ongoing cardiac dysrhythmias of nci ctcae grade ≥2. * pregnant or lactating females or patients who ar not willing to use an adequate method of birth control for the duration of the study
the impact of gender stereotypes on fiberoptic intubation performance

Conditions: Stereotype-threat; Intubation; Difficult or Failed; Gender

Summary: gender bias and stereotypes have been recognized as pervasive factors influencing various aspects of society, including professional settings. within the realm of medical practice, understanding the potential impacts of such biases on performance is of paramount importance. anesthesiology, a field that demands technical precision, teamwork, and rapid decision-making, is not immune to the potential effects of gender stereotypes on performance outcomes. this study aims to explore the potential influence of gender stereotype manipulation and stereotype threat on the fiber-optic intubation (foe) performance of female anesthesiology residents. stereotype threat refers to the apprehension individuals experience when their actions or abilities are evaluated within the context of negative stereotypes associated with their social group. such threat has been shown to adversely affect cognitive and motor performance in various domains. in medical education, where skills are honed through training, understanding the role of stereotype threat is crucial to fostering equitable learning environments and ensuring patient safety.


Eligibility criteria:
inclusion criteria: 1.residents in the department of anesthesiology and reanimation at hacettepe university faculty of medicine, who have completed their initial year of residency and have prior experience in foe. exclusion criteria: 1. not meeting the above criteria 2. not willing to participate in the study

Keywords: gender stereotype fiberoptic intubation
a different use of the aerosol box in covid-19 patients; internal jugular vein cannulation

Conditions: COVID-19 Pneumonia

Summary: during the covid-19 pandemic, health employees are at high risk of infection. this study aimed to determine experiences with an aerosol box (ab), used with the aim of preventing contamination by droplets during internal jugular vein cannulation which requires close contact with covid-19 patients, and the necessity to use this device.

the study included 40 patients with diagnosis of covid-19 requiring central venous catheter during treatment in the ward. the patients were randomly allocated to one of the two protective equipment groups and, then, randomly assigned to one of the five clinicians. group p\&a had both personal protective equipment (ppe) and ab used, while group p included patients where ppe was used alone. clinicians completed a survey after performing the procedure to evaluate the use of the aerosol box. collected data of the procedures and patients, were analyzed. in addition, survey data were evaluated.

Eligibility criteria:
inclusion criteria: * patients diagnosed with covid-19 and inserted central venous catheter while being treated in the ward exclusion criteria: * patients under the age of 18 years * patients who can not lie in the supine position due to severe respiratory distress, * patients with thrombus in the right i̇jv in evaluation with us

Keywords: aerosol box sars-cov-2 virus covid-19 internal jugular vein personal protective equipment
insulin therapy for post-transplant glucocorticoid induced hyperglycemia

Conditions: Post-Transplant Glucocorticoid Induced Diabetes

Summary: no consensus guidelines exist for management of post-transplant glucocorticoid induced hyperglycemia, but most published reviews recommend insulin as first line therapy. a variety of insulin regimens have been proposed, including mealtime short-acting regular or analog insulin, once daily neutral protamine hagedorn (nph) insulin, pre-mixed insulin, or basal insulin alone such as glargine or detemir. however, no randomized trial has ever examined different insulin regimens to determine which most effectively controls post-transplant steroid-induced hyperglycemia. consequently, the proposed study intends to examine three commonly used insulin regimens used for managing post-transplant once-daily glucocorticoid-induced hyperglycemia to determine which is most effective: * group 1: intermediate-acting (nph) insulin at breakfast * group 2: short-acting insulin (regular or aspart) before meals * group 3: insulin glargine at breakfast question/hypothesis: among three commonly used insulin regimens, which is most effective for managing post-transplant once-daily glucocorticoid-induced hyperglycemia?


Eligibility criteria:
inclusion criteria: 1. have undergone bone marrow, liver, lung, or renal transplant. 2. be using once daily oral glucocorticoid therapy (total daily dose of prednisone ≥10 mg, hydrocortisone ≥40 mg, dexamethasone ≥1.5 mg) administered in the morning and expected to continue for at least 2 weeks. 3. have pre-existing or newly diagnosed diabetes mellitus established by any of the criteria listed below: 1. fasting plasma glucose ≥7.0 mmol/l (repeated x 1) 2. any plasma glucose ≥11.0 mmol/l 4. have at least three pre-meal inpatient capillary blood glucose (cbg) readings ≥ 7.8 mmol/l 5. be eating meals by mouth exclusion criteria: 1. heart, pancreas, islet cell transplant recipients 2. previous use of basal-bolus or pre-mixed insulin regimen 3. diabetes mellitus type i 4. npo (not eating meals by mouth) 5. receiving enteral (tube feeds) or parenteral (tpn) nutrition

Keywords: glucocorticoid diabetes mellitus post-transplant insulin